Insider · CIK 0001813667
Stacy Lindborg
Files at IMNN (Imunon, Inc.), BCLI (BRAINSTORM CELL THERAPEUTICS INC.). First filing -, latest -.
In brief
Stacy Lindborg files SEC Form 4 as CEO, president and director at IMNN (Imunon, Inc.), and also at BCLI (BRAINSTORM CELL THERAPEUTICS INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Stacy Lindborg has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 19 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | IMNN Imunon, Inc. | AGrant or award Common Stock | +6,697 | $1.41 | $9,443 | 113,197 | 15 d ago |
| Sep 11, 2026 | IMNN Imunon, Inc. | AGrant or award Common Stock | +5,504 | $1.47 | $8,091 | 105,580 | 28 d ago |
| Aug 28, 2026 | IMNN Imunon, Inc. | AGrant or award Common Stock | +6,822 | $1.60 | $11k | 100,076 | 42 d ago |
| Aug 14, 2026 | IMNN Imunon, Inc. | AGrant or award Common Stock | +6,615 | $1.65 | $11k | 93,254 | Aug 17, 2026 |
| Jul 31, 2026 | IMNN Imunon, Inc. | AGrant or award Common Stock | +5,010 | $1.59 | $7,966 | 86,639 | Aug 4, 2026 |
| Jul 17, 2026 | IMNN Imunon, Inc. | AGrant or award Common Stock | +4,907 | $1.83 | $8,980 | 81,629 | Jul 21, 2026 |
| Jul 2, 2026 | IMNN Imunon, Inc. | AGrant or award Common Stock | +2,534 | $1.91 | $4,840 | 76,722 | Jul 7, 2026 |
| Jun 25, 2026 | IMNN Imunon, Inc. | AGrant or award Common Stock | +67,150 | $1.72 | $115k | 74,188 | Jun 29, 2026 |
| Jun 18, 2026 | IMNN Imunon, Inc. | AGrant or award Common Stock | +1,803 | $1.82 | $3,281 | 7,038 | Jun 23, 2026 |
| Jun 5, 2026 | IMNN Imunon, Inc. | AGrant or award Common Stock | +1,593 | $2.06 | $3,282 | 5,235 | Jun 9, 2026 |
| May 22, 2026 | IMNN Imunon, Inc. | AGrant or award Common Stock | +1,491 | $2.20 | $3,280 | 3,642 | May 27, 2026 |
| Feb 26, 2026 | BCLI BRAINSTORM CELL THERAPEUTICS INC. | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.70 | $105k | 150,000 | May 20, 2026 |
| Jan 2, 2026 | IMNN Imunon, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +56,187 | $0.00 | $0 | 56,187 | Jan 6, 2026 |
| Sep 6, 2025 | IMNN Imunon, Inc. | MOption exercise Common Stock | +1,667 | $0.00 | $0 | 3,584 | Sep 9, 2025 |
| Sep 6, 2025 | IMNN Imunon, Inc. | MOption exercise Restricted Stockderivative | -1,667 | $0.00 | $0 | 0 | Sep 9, 2025 |
| Aug 4, 2025 | IMNN Imunon, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Aug 6, 2025 |
| Mar 14, 2025 | IMNN Imunon, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Mar 18, 2025 |
| Jan 1, 2025 | BCLI BRAINSTORM CELL THERAPEUTICS INC. | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 48,229 | Jan 3, 2025 |
| Sep 6, 2024 | IMNN Imunon, Inc. | AGrant or award Restricted Stock Unitsderivative | +25,000 | $0.00 | $0 | 25,000 | Oct 31, 2024 |
Questions about Stacy Lindborg
Answered from the filings on this page, as of the latest one.
Is Stacy Lindborg buying or selling?
Stacy Lindborg has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Stacy Lindborg's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Stacy Lindborg has 0.
Where does Stacy Lindborg file Form 4?
Stacy Lindborg has filed Form 4 at IMNN (Imunon, Inc.) as President and CEO; BCLI (BRAINSTORM CELL THERAPEUTICS INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.